EU/3/10/732: Orphan designation for the treatment of Hodgkin's lymphoma


Table of contents


On 10 June 2010, orphan designation (EU/3/10/732) was granted by the European Commission to Nexus Oncology Ltd, United Kingdom, for entinostat for the treatment of Hodgkin's lymphoma.


Key facts

Active substance
Intended use
Treatment of Hodgkin's lymphoma
Orphan designation status
EU designation number
Date of designation

Syndax Europe B.V.
Lichttoren 32
5611 BJ Eindhoven

Update history

September 2023The sponsorship was transferred from Propharma Group The Netherlands B.V., Netherlands, to Syndax Europe B.V., Netherlands
April 2022The sponsorship was transferred to Propharma Group The Netherlands B.V., Netherlands
June 2021The sponsor's address was updated.
February 2019The sponsorship was transferred to Southwood Research Limited The Netherlands.
April 2015The sponsorship was transferred to Syndax Limited, United Kingdom
February 2013Nexus Oncology Ltd changed name to Ockham Europe Limited.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating